These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1385140)

  • 1. Preoperative and postoperative evaluation of prostate-specific antigen in localized prostatic cancer treated by radical prostatectomy.
    Zattoni F; Piazza R; Vianello R; Garbeglio A; Pagano F
    Eur Urol; 1992; 21 Suppl 1():99-101. PubMed ID: 1385140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
    Oesterling JE; Chan DW; Epstein JI; Kimball AW; Bruzek DJ; Rock RC; Brendler CB; Walsh PC
    J Urol; 1988 Apr; 139(4):766-72. PubMed ID: 2451037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
    Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
    Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer.
    Thiel R; Pearson JD; Epstein JI; Walsh PC; Carter HB
    Urology; 1997 May; 49(5):716-20. PubMed ID: 9145976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml.
    Ou YC; Chen JT; Cheng CL; Ho HC; Yang CR
    Jpn J Clin Oncol; 2003 Nov; 33(11):574-9. PubMed ID: 14711982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy.
    Goluboff ET; Heitjan DF; DeVries GM; Katz AE; Benson MC; Olsson CA
    J Urol; 1997 Nov; 158(5):1876-8; discussion 1878-9. PubMed ID: 9334621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone as a predictor of pathological stage in clinically localized prostate cancer.
    Isom-Batz G; Bianco FJ; Kattan MW; Mulhall JP; Lilja H; Eastham JA
    J Urol; 2005 Jun; 173(6):1935-7. PubMed ID: 15879785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence after radical prostatectomy for organ-confined prostate cancer.
    Scheepe JR; Vis AN; Mickisch GH
    Onkologie; 2003 Aug; 26(4):330-3. PubMed ID: 12972697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of preoperative PSA in predicting pathologic stage of patients undergoing salvage prostatectomy.
    Younes E; Haas GP; Montie JE; Smith JB; Powell IJ; Pontes JE
    Urology; 1994 Jan; 43(1):22-5. PubMed ID: 7506852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative prostate-specific antigen in predicting pathologic stage and grade after radical prostatectomy.
    Winter HI; Bretton PR; Herr HW
    Urology; 1991 Sep; 38(3):202-5. PubMed ID: 1716021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications.
    Shinohara K; Wolf JS; Narayan P; Carroll PR
    J Urol; 1994 Jul; 152(1):120-3. PubMed ID: 7515447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy.
    Zugor V; Witt JH; Heidenreich A; Porres D; Labanaris AP
    Anticancer Res; 2012 May; 32(5):2091-5. PubMed ID: 22593494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
    Lilja H; Haese A; Björk T; Friedrich MG; Piironen T; Pettersson K; Huland E; Huland H
    J Urol; 1999 Dec; 162(6):2029-34; discussion 2034-5. PubMed ID: 10569562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical and oncological outcomes in patients with a preoperative PSA value <4 ng/ml undergoing robot-assisted radical prostatectomy.
    Zugor V; Labanaris AP; Bauer RM; Witt JH
    Anticancer Res; 2012 May; 32(5):2079-83. PubMed ID: 22593492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.